This edition of Liquid Biopsy for Precision Oncology Summit East Coast has already taken place.
Search future editions →Events › Healthcare & MedTech
Healthcare & MedTech
5th edition
250
Attendees
A 3-day, in-person summit focused on liquid biopsy innovations for precision oncology, covering ctDNA, MRD, and multi-omic profiling.
Attendees: Senior liquid biopsy decision-makers, pharma, biotech & diagnostics leaders, directors of precision oncology.
Exhibitor mix: Partners listed generally, focused on assay development, biospecimen, and technology providers.
Planning for next year?
Dozens of solution providers here. You probably care about 20–30. Tell us your ICP, we'll find them.
Request intelligence →Delivery within 24 hours · $1,250
Organizer
Hanson WadePE-backed · London, United Kingdom · Founded 2008
Hanson Wade is a global conference organizer and market intelligence provider focused primarily on the life sciences and biopharma sectors.
Exhibitor list
10 companies are exhibiting at Liquid Biopsy for Precision Oncology Summit East Coast. The full list is shown below.
Why people attend
To discover new, scalable liquid biopsy platforms and data solutions for clinical development.
Exhibitor categories
Speakers
39 speakers at Liquid Biopsy for Precision Oncology Summit East Coast
Senior Vice President, R&D · Myriad
"Clinical Validation of Myriad Genetics’ Ultra-Sensitive Pan-Cancer WGS-Based Precise MRD Assay"
Also speaking at 11th Annual Liquid Biopsy for Precision Oncology Summit
Senior Scientific Advisor · BioIVT
"The Evolution of Oncology Biomarker Discovery: Why Multi-Omic Strategies are Reshaping Translational Research"
Also speaking at 11th Annual Liquid Biopsy for Precision Oncology Summit
Sr Director, Translational strategy · Guardant Health
"Beyond Companion Diagnostics: How Liquid Biopsy is Transforming Phase 1 Clinical Decision-Making"
Also speaking at 11th Annual Liquid Biopsy for Precision Oncology Summit, Biomarkers, CDx & Precision Medicine Europe
Vice President, Business Development · Biodesix
"From Signal to Strategy: How Liquid Biopsy is Rewriting Drug Development Decisions"
Also speaking at 16th World Clinical Biomarkers & Companion Diagnostics Summit
Senior Scientist II, Quantitative Medicine & Genomics · Abbvie
"Building the ctDNA Blueprint: A Cross-Functional Strategy to Advance Oncology Drug Development"
Director, Precision Medicine · Abbvie
Head, Precision Medicine · Astellas Pharma
Also speaking at 16th World Clinical Biomarkers & Companion Diagnostics Summit
Global Senior Director, Early Detection · AstraZeneca
Senior Director, Cancer Biomarker Development · AstraZeneca
Senior Director & Head, Translational Omics, Hematology R&D · AstraZeneca
Executive Director · BLOODPAC
Also speaking at 16th World Clinical Biomarkers & Companion Diagnostics Summit, 11th Annual Liquid Biopsy for Precision Oncology Summit
executive director · Bristol Myers Squibb
Also speaking at 16th World Clinical Biomarkers & Companion Diagnostics Summit
Head, Clinical Genomics, Global Clinical Biomarkers & Companion Diagnostics · EMD Serono
Also speaking at 16th World Clinical Biomarkers & Companion Diagnostics Summit
Group Lead, Advanced Biostatistical Sciences · EMD Serono
Executive Director, Oncology Translational Medicine · GSK
Scientific Director, Global Diagnostic Lead · Johnson & Johnson
+ 23 more speakers at this event.
More Healthcare & MedTech events
Frequently asked questions